Atorvastatin pretreatment alleviate the ischemic brain injury linked to peroxisome proliferator-activated receptor coactivator-1α and angiogenic factors in diabetic mice.
{"title":"Atorvastatin pretreatment alleviate the ischemic brain injury linked to peroxisome proliferator-activated receptor coactivator-1α and angiogenic factors in diabetic mice.","authors":"Zheng Li, Yun Luo, Jiahui Zhang","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>The purpose of this study was to investigated whether pretreated with Atorvastatin be helpful in diabetic or wild-type mice, and clarify the possible mechanisms.</p><p><strong>Methods: </strong>C57/B6 and ob/ob mice treated with atorvastatin or not were subjected to middle cerebral artery occlusion (MCAO), which were killed after 2h of occlusion following by 22h of reperfusion. We used Neurological Severity Scores (NSS) to assess the severity of brain injury, and TTC staining was used to measure the infraction volume. Protein levels of PGC-1α, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), Bcl2, Bax and signaling pathway protein of mitogen-activated protein kinase (MAPK) were estimated by western blot.</p><p><strong>Results: </strong>Atorvastatin could slake the cerebral ischemic/ reperfusion injury in ob/ob diabetic mice, but do nothing on wild-type mice. The expression of PGC-1α and related angiogenic factors such as VEGF and Ang-1 were lower in the diabetic mice after MCAO than wild-type, which could be effective reversed by atorvastatin pretreatment before MCAO. This may be one of the possible mechanisms for atorvastatin to alleviate ischemic injury. MAPK pathway and apoptosis-related proteins were also involved in this course.</p><p><strong>Conclusion: </strong>Impaired angiogenesis mediated by PGC-1α plays an important role in exacerbating ischemic cerebral insults in diabetic mice, and pretreatment with atorvastatin before MCAO has a protective effect through the regulation of PGC-1α and angiogenic factors.</p>","PeriodicalId":19098,"journal":{"name":"Neuro endocrinology letters","volume":"42 5","pages":"331-338"},"PeriodicalIF":0.6000,"publicationDate":"2021-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Neuro endocrinology letters","FirstCategoryId":"3","ListUrlMain":"","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
Objective: The purpose of this study was to investigated whether pretreated with Atorvastatin be helpful in diabetic or wild-type mice, and clarify the possible mechanisms.
Methods: C57/B6 and ob/ob mice treated with atorvastatin or not were subjected to middle cerebral artery occlusion (MCAO), which were killed after 2h of occlusion following by 22h of reperfusion. We used Neurological Severity Scores (NSS) to assess the severity of brain injury, and TTC staining was used to measure the infraction volume. Protein levels of PGC-1α, vascular endothelial growth factor (VEGF), angiopoietin-1 (Ang-1), Bcl2, Bax and signaling pathway protein of mitogen-activated protein kinase (MAPK) were estimated by western blot.
Results: Atorvastatin could slake the cerebral ischemic/ reperfusion injury in ob/ob diabetic mice, but do nothing on wild-type mice. The expression of PGC-1α and related angiogenic factors such as VEGF and Ang-1 were lower in the diabetic mice after MCAO than wild-type, which could be effective reversed by atorvastatin pretreatment before MCAO. This may be one of the possible mechanisms for atorvastatin to alleviate ischemic injury. MAPK pathway and apoptosis-related proteins were also involved in this course.
Conclusion: Impaired angiogenesis mediated by PGC-1α plays an important role in exacerbating ischemic cerebral insults in diabetic mice, and pretreatment with atorvastatin before MCAO has a protective effect through the regulation of PGC-1α and angiogenic factors.
期刊介绍：
Neuroendocrinology Letters is an international, peer-reviewed interdisciplinary journal covering the fields of Neuroendocrinology, Neuroscience, Neurophysiology, Neuropsychopharmacology, Psychoneuroimmunology, Reproductive Medicine, Chronobiology, Human Ethology and related fields for RAPID publication of Original Papers, Review Articles, State-of-the-art, Clinical Reports and other contributions from all the fields covered by Neuroendocrinology
Letters.
Papers from both basic research (methodology, molecular and cellular biology, anatomy, histology, biology, embryology, teratology, normal and pathological physiology, biophysics, pharmacology, pathology and experimental pathology, biochemistry, neurochemistry, enzymology, chronobiology, receptor studies, endocrinology, immunology and neuroimmunology, animal physiology, animal breeding and ethology, human ethology, psychology and others) and from clinical research (neurology, psychiatry and child psychiatry, obstetrics and gynecology, pediatrics, endocrinology, immunology, cardiovascular studies, internal medicine, oncology and others) will be considered.
The Journal publishes Original papers and Review Articles. Brief reports, Special Communications, proved they are based on adequate experimental evidence, Clinical Studies, Case Reports, Commentaries, Discussions, Letters to the Editor (correspondence column), Book Reviews, Congress Reports and other categories of articles (philosophy, art, social issues, medical and health policies, biomedical history, etc.) will be taken under consideration.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
